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Abstract
Background: Although there are considerable data regarding in-hospital results of congenital heart surgery (CHS) patients
requiring postoperative extracorporeal membrane oxygenation (ECMO) support, there is limited information on
intermediate-term outcomes. Methods: A single-institution retrospective review of 25 consecutive postoperative CHS patients
who required ECMO and survived to hospital discharge between January 2003 and June 2008. Survival was estimated by the
Kaplan-Meier method. Results: At a median follow-up of 3.3 years (interquartile range: 1.2-5.9 years), there was one death which
occurred at six months postsurgery. Kaplan-Meier-estimated survival at three years was 95% (95% confidence interval: 90%-
100%). Indications for ECMO included extracorporeal cardiopulmonary resuscitation (48%), systemic hypoxia (4%), postopera-
tive low-cardiac output syndrome (28%), and intraoperative failure to wean off cardiopulmonary bypass (20%). Following ECMO
support, 65% of patients had unplanned cardiac reinterventions (three requiring operative interventions, six requiring percuta-
neous interventions, and four requiring both), and 47% of patients required unplanned hospitalizations. In all, 29% of patients
developed neurological deficits and 12% of patients developed chronic respiratory failure. No patients developed renal failure.
Overall, systemic ventricular (SV) function normalized in 83% of patients, whereas 17% of patients had persistent mild-to-
moderate SV dysfunction. Conclusions: Intermediate-term patient survival of ECMO following CHS is encouraging. However,
neurological impairment and unplanned cardiac reinterventions remain significant concerns. Further delineation of risk factors to
improve patient outcomes is warranted.
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Introduction
In patients undergoing palliative congenital heart surgery
(CHS), extracorporeal membrane oxygenation (ECMO) was
first described as a method of resuscitation and support in
19701 and is now a well-accepted and cost-effective modality
for the treatment of patients with significant cardiac or
respiratory compromise.2 The overall survival to discharge
of neonatal and pediatric patients placed on ECMO for car-
diac indications is 40% and 49%, respectively.3 Survival of
patients requiring ECMO for respiratory indications is more
favorable than for patients requiring ECMO for cardiac sup-
port.4 Although the indications for ECMO have broadened
since its inception, the survival rates reported have been con-
stant over the years. Post-ECMO morbidity remains a signif-
icant concern, and long duration of ECMO support, acidemia,
low-urine output in the first 24 hours, renal failure, and
neurological impairment have been established as some of
the risk factors associated with short-term morbidity and
mortality.5,6
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AICD automatic implantable cardioverter
defibrillator
CHS congenital heart surgery
ECMO extracorporeal membrane oxygenation
SV systemic ventricular
Although recent studies have reported survival rates of up to
55% in neonatal and pediatric patients receiving ECMO for
cardiac indications, 40% to 60% of these survivors have new
neurological deficits.7 These high long-term morbidity and
mortality rates, as well as the high resource utilization associ-
ated with ECMO, raise concerns about the overly aggressive
use of ECMO in CHS patients. Although short-term morbidity
and mortality are well established, there are few data available
on the intermediate- and long-term outcomes for these patients
to help guide clinical decision making. This study seeks to
examine the intermediate-term outcomes for patients who
receive ECMO after CHS.
Patients and Methods
After obtaining institutional review board approval, a retro-
spective medical record review was performed to identify all
patients who required post-CHS ECMO support and survived
until hospital discharge at Children’s National Medical Center
from January 2003 to June 2008. Twenty-five patients were
identified and selected for further review. Both inpatient and
outpatient records were analyzed for demographic and out-
comes data. Statistical analyses were performed using IBM
SPSS Statistics (version 21.0, IBM, Armonk, New York). Con-
tinuous variables are expressed as median and interquartile
range. Kaplan-Meier survival analysis was utilized to assess
patient survival with a 95% confidence interval based on
Greenwood’s formula. New neurological deficits were defined
as motor and cognitive abnormalities diagnosed following
post-CHS ECMO support. Chronic respiratory failure was
defined as tracheostomy/ventilator dependence at one year fol-
lowing discharge. Unplanned cardiac reinterventions were
defined as any interventions (other than planned, staged single
ventricle palliation) following complete operative repair,
including interstage interventions in single-ventricle disease.
Unplanned hospitalizations were defined as any hospitaliza-
tions not related to planned, staged single-ventricle palliative
procedures. Renal failure was defined as the need for hemodia-
lysis or peritoneal dialysis.
Results
In this single-institution retrospective review, 25 consecutive
post-CHS ECMO patients who survived to hospital discharge
were followed for a mean period of 3.3 years (interquartile
range: 1.2-5.9 years; Table 1). Of the 25 patients, 18 (72%)
underwent biventricular surgical repair and 7 (28%) underwent
single-ventricle palliation. A summary of the cardiac diagnoses
of the study patients is documented in Table 2. Median age at
the time of ECMO initiation was four months. Indications for
the use of ECMO in these patients included extracorporeal car-
diopulmonary resuscitation (48%), postoperative low-cardiac
output syndrome (28%), intraoperative failure to wean off car-
diopulmonary bypass (20%), and hypoxia (4%; Table 3). In all,
two patients were lost-to-follow-up immediately following dis-
charge (one was a foreign national who returned to her home
country; one for unknown reasons); three additional patients
Table 1. Summary of Patient Demographics and Characteristics.a
Variable Total Patients, N ¼ 25
Male gender, no (%) 13 (52)
Female gender, no (%) 12 (48)
Age at ECMO, days 124 (5-437)
Weight, kg 3.5 (2.9-8.5)




Concurrent genetic syndromes, no (%) 4 (16)
Duration of hospitalization, days 48 (33-74)
Duration of follow-up, years 3.3 (1.2-5.9)
Abbreviations: ECMO, extracorporeal membrane oxygenation; no, number.
a Continuous variables are median (interquartile range).
Table 2. Summary of Patient Cardiac Diagnoses.
Cardiac Diagnosis Total Patients, N ¼ 25
Cyanosis with increased PBF, no (%) 3 (12)
Cyanosis with decreased PBF, no (%) 12 (48)
Left-sided obstructive lesions, no (%) 5 (20)
Left-to-right shunt, no (%) 2 (8)
Hypoplastic left heart syndrome, no (%) 2 (8)
Anomalous origin of coronary artery, no (%) 1 (4)
Abbreviations: PBF, pulmonary blood flow; no, number.
Table 3. Clinical Summary.
Variable Total Patients, N ¼ 25
Indications for ECMO, no (%)
E-CPR 12 (48)
Post-operative low-cardiac output 7 (28)
Intra-operative failure to wean from CPB 5 (20)
Hypoxia 1 (4)
Secondary end points, no (%)
Neurological deficits 5a (22)
Chronic respiratory failure 3 (12)
Unplanned cardiac reinterventions 13a (65)
Unplanned hospitalizations 9a (39)
Renal failure 0 (0)
Normalization of SV function 19a (83)
Abbreviations: CPB, cardiopulmonary bypass; ECMO, extracorporeal
membrane oxygenation; E-CPR, extracorporeal cardiopulmonary resuscita-
tion; SV, systemic ventricular; no, number.
a Neurological deficits, unplanned hospitalizations, and normalization of SV
function are based on 23 patients available for follow-up; unplanned cardiac
reinterventions are based on 20 patients available for long-term follow-up.
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were lost to follow-up within the first year following discharge
(two were foreign nationals returning to their home countries;
one for unknown reasons), and a single patient died at six
months postsurgery. In summary, 23 patients had follow-up
after discharge, and a total of 20 patients had long-term (greater
than nine months) follow-up. Overall, Kaplan-Meier estimated
survival was 95% at three years postdischarge (95% confidence
interval: 90%-100%; Figure 1).
Regarding long-term morbidities, 22% (n ¼ 5) of patients
developed new neurological deficits after ECMO, and 12%
(n ¼ 3) of patients were tracheostomy/ventilator dependent
following discharge. In all, 39% (n ¼ 9) of patients with
follow-up had unplanned hospitalizations, and 65% (n ¼ 13)
of patients with long-term follow-up had unplanned cardiac
interventions: three required surgical interventions, six required
percutaneous interventions, and four required both percutaneous
and surgical interventions. No patients developed renal failure
following post-CHS ECMO support. Systemic ventricular
(SV) function normalized in 83% (n ¼ 19) of patients with
follow-up, while the remaining 17% (n¼ 4) of patients had per-
sistent mild-to-moderate SV dysfunction (Table 3).
Medical technology dependence, defined here as reliance
on specialized equipment on a day-to-day basis, varied during
the follow-up period (Figure 2). Over the three-year course of
this study, dependence on tracheostomy included three
patients at one year, and one patient at two and three years,
whereas dependence on gastrostomy tube feeding varied from
five to eight patients. At each time point, two patients required
automatic implantable cardioverter defibrillator (AICD)/
pacemakers.
Comment
Since its early use, ECMO has become an important tool in the
modern critical care armamentarium to aid the exceptionally ill
patients when cardiopulmonary support is required. There are
many advantages to the use of ECMO in pediatric cardiac
patients, including both cardiac and pulmonary support, sup-
port for various cardiac anatomies, rapid implementation, ver-
satility, and current extensive experience. However, this
technology is not without significant potential associated mor-
bidities, including the risk of hemorrhagic or thrombotic com-
plications, transfusion requirements, and neurological deficits.8
These potential complications typically limit the safe and
effective duration of ECMO to days or weeks and have raised
concerns regarding the possibility of overly aggressive use of
this technology.
Within the pediatric cardiac patient population, ECMO is
typically used as a form of extended resuscitation for patients
who have potentially reversible causes of cardiac dysfunction
but are refractory to standard resuscitation attempts.9 The spe-
cific indications for ECMO in the present study are similar to
those reported previously.10 However, morbidity following
ECMO has been a major concern since its inception. Although
these patients may survive the period of ECMO support and
survive to hospital discharge, they often have persistent medi-
cal problems that require further intervention or long-term care.
This is reflected in several of the outcomes examined in this
study. The rates of further unplanned cardiac interventions and
hospitalizations were 65% and 39%, respectively, within our
cohort, similar to previously reported data.11-14 In our cohort,
12% of patients had chronic respiratory failure, with all of these
patients being tracheostomy dependent at one-year post-
discharge. In addition, ongoing neurologic dysfunction, a
long-established ECMO-associated morbidity, was noted to
be present in five of our patients, again similar to previously
reported results.6,10 Although not associated with higher mor-
tality, neurological complications represent a source of great
morbidity for this population,15 and the associated costs,
long-term care requirements, and strain on caregivers can be
tremendous and must be acknowledged when considering
initiation of ECMO. Long-term quality-of-life implications due
to these morbidities, especially new neurologic dysfunction,
Figure 1. Kaplan-Meier survival curve based on 25 patients (one
death at six months post-surgery). Error bars denote 95% confidence
intervals based on Greenwood’s formula.
Figure 2. Medical technology dependence, defined here as reliance
on specialized equipment on a day-to-day basis, among survivors of
ECMO support following congenital heart surgery.
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have yet to be examined, and further study to establish the long-
term impact that these morbidities have is warranted.
A number of patients in our study cohort had medical technol-
ogy dependence during the follow-up period (Figure 2). Not sur-
prisingly, AICD/pacemaker dependence was ongoing throughout
this period. We speculate that the observed changes in medical
technology dependence over time likely reflect a global improve-
ment in function for these patients, and freedom from these tech-
nologies may be seen as a surrogate marker for improved quality
of life. At the very least, it is a marker of decreased dependence on
medical intervention and also represents a decrease in caregiver
burden. However, as complete functional assessments and
quality-of-life measurements were not undertaken, these results
are speculative. Further study is needed to fully understand the
effects that these changes have over time in an effort to better
determine the ultimate quality of life that these patients attain
on a long-term basis.
Finally, our data indicate that, within our population, the
majority (83%) of patients went on to regain SV function. The
persistent dysfunction present in the remaining patients was of
mild-to-moderate severity. As this study did not examine the
level of cardiac function for those patients who did not survive
to discharge, this result may be due, in part, to the fact that
those who had a return of cardiac function were more likely
to survive to discharge. These results are, however, encoura-
ging in that they suggest that long-term cardiac function does
not appear to be negatively affected by the use of ECMO.
This study has several limitations. Due to the relative infre-
quency of ECMO utilization post-CHS at our institution, our
sample size is small. Specifically, at our institution the inci-
dence of ECMO use in pediatric patients following CHS as a
percentage of the total number of all congenital heart opera-
tions performed during the study period was as follows:
2003—3.4%, 2004—1.0%, 2005—3.8%, 2006—1.9%,
2007—4.7%, and 2008—4.3% (mean overall annual incidence
during the study period—3.2%). In the published literature, the
reported incidence of ECMO support following CHS is 1% to
5%,16 with some centers reporting an incidence as high as
8.5%.17 Of note, our institution’s use of ECMO following CHS
(as a percentage of the total number of all congenital heart
operations performed) has decreased significantly in 2011
(1.4%) and 2012 (0.9%).
A meaningful assessment of risk factors for intermediate-
term morbidity in the study patients was not feasible as the
sample size was too small to allow for sufficient power for sta-
tistical comparison and multivariate logistic regression analy-
sis. Likewise, we could not analyze the risk factors for
mortality for a given cardiac diagnosis due to low statistical
power. However, although our patient sample size is small,
we believe that our study results are clinically important as
there are very limited data available on the intermediate- and
long-term outcomes of patients who survive ECMO following
CHS. We feel that our study demonstrates the need and may
provide impetus for a large, multi-institution study that is suf-
ficiently powered to definitively evaluate intermediate- and
long-term outcomes and risk factors for morbidity and
mortality based on specific cardiac diagnoses in this critically
ill patient population.
As part of our data collection, we administered a well-
validated quality-of-life questionnaire by telephone and mail
(specifically, the PedsQL Measurement Model, utilizing both
the PedsQL Pediatric Quality of Life Inventory Version 4.0
[validated in healthy children and adolescents and those with
acute and chronic health conditions]18 and the PedsQL Cardiac
Module Version 3.0 [validated in patients with heart dis-
ease]19). However, the participation/response rate in this ques-
tionnaire was very low and, hence, we were unable to
determine patient-reported assessments of quality of life. As
many of the study patients have relocated away from our insti-
tution’s geographic area, bringing these patients back to our
institution for in-person quality-of-life assessments was not
feasible.
Overall, further study is needed to better understand how,
from the patient and caregiver perspectives, morbidities affect
patients in the long term. This will better establish the ongoing
quality of life that these individuals experience and help iden-
tify the obstacles they face going forward. Ultimately, we con-
tinue to believe that ECMO is a valuable clinical tool for
management of the critically-ill CHS population, and it will
continue to remain an essential part of our treatment strategy
in caring for these complex and challenging patients.
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